Royal Bank of Canada’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-4,659
| Closed | -$155K | – | 7772 |
|
|
2026
Q1 | $155K | Sell |
4,659
-4,997
| -52% | -$196K | ﹤0.01% | 4865 |
|
|
2025
Q4 | $447K | Buy |
9,656
+9,267
| +2,382% | +$508K | ﹤0.01% | 4253 |
|
|
2025
Q3 | $26K | Buy |
389
+51
| +15% | +$3.78K | ﹤0.01% | 6107 |
|
|
2025
Q2 | $29K | Sell |
338
-2,220
| -87% | -$166K | ﹤0.01% | 6142 |
|
|
2025
Q1 | $182K | Buy |
2,558
+2,033
| +387% | +$99K | ﹤0.01% | 4770 |
|
|
2024
Q4 | $24K | Sell |
525
-2,120
| -80% | -$110K | ﹤0.01% | 6045 |
|
|
2024
Q3 | $133K | Buy |
2,645
+576
| +28% | +$27.6K | ﹤0.01% | 5150 |
|
|
2024
Q2 | $84K | Buy |
2,069
+1,979
| +2,199% | +$83.9K | ﹤0.01% | 5368 |
|
|
2024
Q1 | $4K | Buy |
+90
| New | +$4.07K | ﹤0.01% | 6529 |
|
|
2023
Q1 | – | Sell |
-6
| Closed | – | – | 7429 |
|
|
2022
Q4 | $0 | Sell |
6
-3
| -33% | -$4 | ﹤0.01% | 7665 |
|
|
2022
Q3 | $0 | Hold |
9
| – | – | ﹤0.01% | 7813 |
|
|
2022
Q2 | $0 | Hold |
9
| – | – | ﹤0.01% | 7682 |
|
|
2022
Q1 | $0 | Sell |
9
-10
| -53% | -$52 | ﹤0.01% | 7985 |
|
|
2021
Q4 | $0 | Hold |
19
| – | – | ﹤0.01% | 7868 |
|
|
2021
Q3 | $0 | Sell |
19
-240
| -93% | -$3.35K | ﹤0.01% | 7845 |
|
|
2021
Q2 | $4K | Sell |
259
-82
| -24% | -$1.39K | ﹤0.01% | 7130 |
|
|
2021
Q1 | $6K | Buy |
341
+16
| +5% | +$516 | ﹤0.01% | 7002 |
|
|
2020
Q4 | $9K | Buy |
325
+321
| +8,025% | +$9.26K | ﹤0.01% | 6442 |
|
|
2020
Q3 | $0 | Buy |
+4
| New | +$117 | ﹤0.01% | 6904 |
|
|
2020
Q2 | – | Sell |
-36
| Closed | -$1K | – | 6882 |
|
|
2020
Q1 | $1K | Hold |
36
| – | – | ﹤0.01% | 6487 |
|
|
2019
Q4 | $2K | Sell |
36
-2
| -5% | -$51 | ﹤0.01% | 6573 |
|
|
2019
Q3 | $1K | Buy |
38
+37
| +3,700% | +$1.18K | ﹤0.01% | 6509 |
|
|
2019
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 7146 |
|
|
2019
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7064 |
|
|
2018
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 7078 |
|
|
2018
Q3 | $0 | Buy |
+1
| New | +$36 | ﹤0.01% | 6929 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6740 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6747 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6844 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6951 |
|
Royal Bank of Canada's SLNO Position: Q2 2026 in Review
Royal Bank of Canada sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 4,659 shares — an estimated $155K sold.
Royal Bank of Canada first reported a position in SLNO in Q3 2018 and held it in 26 quarters. The position peaked at $447K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Royal Bank of Canada reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Royal Bank of Canada sold 4,659 Soleno Therapeutics shares in Q2 2026, an estimated $155K.
- Royal Bank of Canada first reported a position in Soleno Therapeutics in Q3 2018 and held it in 26 quarters.
- Royal Bank of Canada's Soleno Therapeutics position peaked at $447K in Q4 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.